



HSE Prescribing Protocol
for the treatment of adult patients with moderately to severely active
Crohn's Disease

Risankizumab (Skyrizi®)

This document is intended for use by healthcare professionals only.

This guideline should be used in conjunction with the full prescribing and administration details in the
Risankizumab (Skyrizi®) Summary of Product Characteristics (SmPC)

https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf

INDICATION FOR USE¹

TREATMENT	HSE APPROVED INDICATION	ICD10	PROTOCOL CODE
Risankizumab	Treatment of adult patients with moderately to severely active Crohn's Disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy* or a biologic therapy [‡] . Risankizumab is restricted to use by the HSE as a second or subsequent line of therapy following treatment with a lower cost biological therapy [‡] .	K50	Gastro001

*Conventional Therapy (for CD):

- Thiopurines (azathioprine or 6-mercaptopurine) +/- allopurinol
- Methotrexate (subcutaneous or oral)

[‡]First line Biological therapy Options:

- Infliximab
- Adalimumab
- Ustekinumab
- Vedolizumab

Please contact your pharmacy department for pricing arrangements for relevant agent(s).

TREATMENT¹

Crohn's Disease

Risankizumab	DOSE	ROUTE	DURATION OF THERAPY
Induction	600mg	IV	At week 0, 4 and 8
Maintenance	360mg	Subcutaneously	At week 12 and then every 8 weeks thereafter

ELIGIBILITY CRITERIA

- Patients 18 years or over
- Patients with moderate to severe Crohn's Disease
- Patients who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic therapy (as defined above)

Guideline: HSE Prescribing Protocol for the treatment of adult patients with moderately to severely active Crohn's Disease		Published: October 2025 Review: October 2027	Version number: 1
Protocol Code: GASTRO001	Approved by: Dr Mike O'Connor National Clinical Advisor & Group Lead, Acute Hospitals	Contributors: AIDMP and Professor Aoibhlinn O'Toole, Consultant Gastroenterologist and IBD Working Group Lead, National Clinical Programme for Gastroenterology & Hepatology.	Page 2 of 4
Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check: https://www.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/protocols/rare-diseases.html			

EXCLUSION CRITERIA

Patients who do not meet the eligibility criteria

CONTRAINDICATIONS

- Hypersensitivity to the active substance or to any of the excipients listed in SmPC
- Clinically important active infections as per SmPC

BASELINE TESTS AND MONITORING

As stipulated by the clinical team.

SPECIAL WARNINGS AND PRECAUTION FOR USE

See SmPC

STOPPING CRITERIA

Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by week 24¹.

ADVERSE EFFECTS

See SmPC

OTHER INFORMATION

Missed dose¹

If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time

DRUG INTERACTIONS

See SmPC

ATC CODE

Immunosuppressants, interleukin inhibitors L04AC18

REIMBURSEMENT CATEGORY

Induction: Risankizumab (Skyrizi®) 600mg concentrate for solution for infusion is managed within local hospital budget

Maintenance: Risankizumab (Skyrizi®) 360mg solution for injection in cartridge is available via High Tech Hub arrangements

Guideline: HSE Prescribing Protocol for the treatment of adult patients with moderately to severely active Crohn's Disease		Published: October 2025 Review: October 2027	Version number: 1
Protocol Code: GASTRO001	Approved by: Dr Mike O'Connor National Clinical Advisor & Group Lead, Acute Hospitals	Contributors: AIDMP and Professor Aoibhlinn O'Toole, Consultant Gastroenterologist and IBD Working Group Lead, National Clinical Programme for Gastroenterology & Hepatology.	Page 3 of 4
Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check: https://www.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/protocols/rare-diseases.html			

REFERENCES

1. Summary of Product Characteristics, Skyrizi 600mg concentrate for solution for infusion. Available from https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf. Accessed on: 04 September 2025

APPENDIX

Revision History

Revision Number	Revision Date	Summary of Changes

Guideline: HSE Prescribing Protocol for the treatment of adult patients with moderately to severely active Crohn's Disease		Published: October 2025 Review: October 2027	Version number: 1
Protocol Code: GASTRO001	Approved by: Dr Mike O'Connor National Clinical Advisor & Group Lead, Acute Hospitals	Contributors: AIDMP and Professor Aoibhlinn O'Toole, Consultant Gastroenterologist and IBD Working Group Lead, National Clinical Programme for Gastroenterology & Hepatology.	Page 4 of 4
Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check: https://www.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/protocols/rare-diseases.html			